BI 1820237 and Liraglutide combination tolerability and pharmacokinetics to be assessed in overweight men
A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide
Abstract
A Phase 1 trial will evaluate safety, tolerability, and pharmacokinetics of BI 1820237 alone or with liraglutide in overweight/obese men.